Logo image of BON

BON NATURAL LIFE LTD-A (BON) Stock Fundamental Analysis

NASDAQ:BON - Nasdaq - KYG144921213 - Common Stock - Currency: USD

1.53  -0.08 (-4.97%)

After market: 1.51 -0.02 (-1.31%)

Fundamental Rating

4

Overall BON gets a fundamental rating of 4 out of 10. We evaluated BON against 85 industry peers in the Chemicals industry. While BON seems to be doing ok healthwise, there are quite some concerns on its profitability. BON is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year BON was profitable.
BON had a negative operating cash flow in the past year.
In the past 5 years BON has always been profitable.
In multiple years BON reported negative operating cash flow during the last 5 years.
BON Yearly Net Income VS EBIT VS OCF VS FCFBON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

1.2 Ratios

BON's Return On Assets of 0.64% is in line compared to the rest of the industry. BON outperforms 47.06% of its industry peers.
With a Return On Equity value of 0.91%, BON perfoms like the industry average, outperforming 45.88% of the companies in the same industry.
BON has a worse Return On Invested Capital (2.44%) than 67.06% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BON is in line with the industry average of 6.84%.
The last Return On Invested Capital (2.44%) for BON is well below the 3 year average (8.52%), which needs to be investigated, but indicates that BON had better years and this may not be a problem.
Industry RankSector Rank
ROA 0.64%
ROE 0.91%
ROIC 2.44%
ROA(3y)9.09%
ROA(5y)10.38%
ROE(3y)11.65%
ROE(5y)16.28%
ROIC(3y)8.52%
ROIC(5y)10.57%
BON Yearly ROA, ROE, ROICBON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

BON has a Profit Margin (1.67%) which is in line with its industry peers.
In the last couple of years the Profit Margin of BON has declined.
With a Operating Margin value of 7.86%, BON perfoms like the industry average, outperforming 45.88% of the companies in the same industry.
BON's Operating Margin has declined in the last couple of years.
BON has a Gross Margin (29.82%) which is in line with its industry peers.
In the last couple of years the Gross Margin of BON has declined.
Industry RankSector Rank
OM 7.86%
PM (TTM) 1.67%
GM 29.82%
OM growth 3Y-28.15%
OM growth 5Y-16.51%
PM growth 3Y-54.74%
PM growth 5Y-36.12%
GM growth 3Y2.25%
GM growth 5Y-1.53%
BON Yearly Profit, Operating, Gross MarginsBON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 10 20 30

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BON is creating value.
Compared to 1 year ago, BON has more shares outstanding
The number of shares outstanding for BON has been increased compared to 5 years ago.
BON has a worse debt/assets ratio than last year.
BON Yearly Shares OutstandingBON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K
BON Yearly Total Debt VS Total AssetsBON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

BON has an Altman-Z score of 1.44. This is a bad value and indicates that BON is not financially healthy and even has some risk of bankruptcy.
BON has a worse Altman-Z score (1.44) than 64.71% of its industry peers.
BON has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.15, BON belongs to the top of the industry, outperforming 83.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 1.44
ROIC/WACC0.58
WACC4.17%
BON Yearly LT Debt VS Equity VS FCFBON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 2.42 indicates that BON has no problem at all paying its short term obligations.
BON has a better Current ratio (2.42) than 64.71% of its industry peers.
BON has a Quick Ratio of 2.32. This indicates that BON is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.32, BON belongs to the top of the industry, outperforming 84.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.32
BON Yearly Current Assets VS Current LiabilitesBON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

4

3. Growth

3.1 Past

The earnings per share for BON have decreased strongly by -97.84% in the last year.
The earnings per share for BON have been decreasing by -44.75% on average. This is quite bad
Looking at the last year, BON shows a very negative growth in Revenue. The Revenue has decreased by -19.23% in the last year.
Measured over the past years, BON shows a small growth in Revenue. The Revenue has been growing by 7.78% on average per year.
EPS 1Y (TTM)-97.84%
EPS 3Y-71.08%
EPS 5Y-44.75%
EPS Q2Q%-95.59%
Revenue 1Y (TTM)-19.23%
Revenue growth 3Y-2.21%
Revenue growth 5Y7.78%
Sales Q2Q%-11.13%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 24.08% on average over the next years. This is a very strong growth
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year77.63%
Revenue Next 2Y45.28%
Revenue Next 3Y34.64%
Revenue Next 5Y24.08%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BON Yearly Revenue VS EstimatesBON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M 100M
BON Yearly EPS VS EstimatesBON Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 50 100 150

3

4. Valuation

4.1 Price/Earnings Ratio

BON is valuated cheaply with a Price/Earnings ratio of 0.57.
Compared to the rest of the industry, the Price/Earnings ratio of BON indicates a rather cheap valuation: BON is cheaper than 98.82% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BON to the average of the S&P500 Index (26.31), we can say BON is valued rather cheaply.
Industry RankSector Rank
PE 0.57
Fwd PE N/A
BON Price Earnings VS Forward Price EarningsBON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

98.82% of the companies in the same industry are more expensive than BON, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.54
BON Per share dataBON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for BON!.
Industry RankSector Rank
Dividend Yield N/A

BON NATURAL LIFE LTD-A

NASDAQ:BON (6/13/2025, 8:00:02 PM)

After market: 1.51 -0.02 (-1.31%)

1.53

-0.08 (-4.97%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)09-22 2025-09-22
Inst Owners1.59%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap260.10K
Analysts0
Price TargetN/A
Short Float %N/A
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.57
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B 0.01
P/tB 0.01
EV/EBITDA 0.54
EPS(TTM)2.7
EY176.47%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-45.47
FCFYN/A
OCF(TTM)-45.43
OCFYN/A
SpS140.26
BVpS258.27
TBVpS253.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.64%
ROE 0.91%
ROCE 4.13%
ROIC 2.44%
ROICexc 2.44%
ROICexgc 2.48%
OM 7.86%
PM (TTM) 1.67%
GM 29.82%
FCFM N/A
ROA(3y)9.09%
ROA(5y)10.38%
ROE(3y)11.65%
ROE(5y)16.28%
ROIC(3y)8.52%
ROIC(5y)10.57%
ROICexc(3y)8.65%
ROICexc(5y)11.01%
ROICexgc(3y)8.8%
ROICexgc(5y)11.18%
ROCE(3y)13.84%
ROCE(5y)17.18%
ROICexcg growth 3Y-44.37%
ROICexcg growth 5Y-33.89%
ROICexc growth 3Y-44.35%
ROICexc growth 5Y-33.92%
OM growth 3Y-28.15%
OM growth 5Y-16.51%
PM growth 3Y-54.74%
PM growth 5Y-36.12%
GM growth 3Y2.25%
GM growth 5Y-1.53%
F-Score2
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA 2.24
Cap/Depr 0.64%
Cap/Sales 0.03%
Interest Coverage 6.18
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.32
Altman-Z 1.44
F-Score2
WACC4.17%
ROIC/WACC0.58
Cap/Depr(3y)764.29%
Cap/Depr(5y)1250.29%
Cap/Sales(3y)6.63%
Cap/Sales(5y)12.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.84%
EPS 3Y-71.08%
EPS 5Y-44.75%
EPS Q2Q%-95.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.23%
Revenue growth 3Y-2.21%
Revenue growth 5Y7.78%
Sales Q2Q%-11.13%
Revenue Next Year77.63%
Revenue Next 2Y45.28%
Revenue Next 3Y34.64%
Revenue Next 5Y24.08%
EBIT growth 1Y-68.34%
EBIT growth 3Y-29.74%
EBIT growth 5Y-10.01%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-319.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1084.66%
OCF growth 3YN/A
OCF growth 5YN/A